Expanding Product Portfolio: The iStent portfolio significantly boosted Glaukos' glaucoma franchise revenues in 2024. Additionally, the launch of iDose TR in the second quarter of 2024 is already ...

Minimally invasive glaucoma surgeries, like the iStent inject and Xen Gel Stent, are crucial for preventing disease progression. Technological innovations, including AI-driven diagnostics and ...

to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject ...

Glaucoma is a disease that causes optic nerve damage and potential blindness, impacting millions globally. Often asymptomatic, it’s dubbed the 'silent thief of sight.' Regular eye check-ups are ...

Glaucoma is a group of eye diseases that leads to vision loss. It’s often without other symptoms and is due to damage to the optic nerve, which transfers visual information from the retina to ...

Key products include the iStent and iStent inject W micro-bypass stents for treating open-angle glaucoma and the iDose TR, an intracameral implant that delivers glaucoma medication for up to three ...

With over 20 years of experience, he has pioneered minimally invasive glaucoma surgeries (MIGS), including Trabectome, iStent and canaloplasty, transforming patient care. His research also focuses ...